Aipu Regenerative Medicine Technology

Aipu Regenerative Medicine is a clinical-stage biotechnology company specializing in the development of regenerative therapies for skin and hair disorders. Founded by a team led by Academician Fu Xiaobing, the company utilizes proprietary cell therapy platforms to address unmet needs in dermatology and wound care. Their lead program, AP-001, is an autologous cell therapy currently in Phase 2 clinical trials for the treatment of androgenetic alopecia. The company also develops treatments for chronic wounds, such as diabetic foot ulcers, and aesthetic applications using skin-derived precursor cells. Aipu operates out of Taizhou's China Medical City and maintains a research presence in Shanghai.